Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease.
The issue of the interplay of optimal dosage and frequency regimens for enzyme replacement therapy in type I Gaucher disease has been a source of controversy during the 7 years since the introduction of the placenta-derived enzymatic preparation in 1991. We present the results of treatment with the human recombinant form of the enzyme in 28 type I Gaucher patients, who have been treated for 6 to 24 months. As long as cost is an important factor in the management of patients with Gaucher disease, low-dose low-frequency imiglucerase promises satisfactory clinical improvement without compromising quality of life.
Elstein
D
D
Gaucher Clinic, Shaare-Zedek Medical Center, Jerusalem, Israel.
Abrahamov
A
A
Hadas-Halpern
I
I
Meyer
A
A
Zimran
A
A
D000293:Adolescent; D000328:Adult; D001792:Blood Platelets; D004334:Drug Administration Schedule; D005260:Female; D005776:Gaucher Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D005962:Glucosylceramidase / Q000008:administration & dosage*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008099:Liver / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage; D013154:Spleen / Q000473:pathology
D006454:Hemoglobins; D011994:Recombinant Proteins; D005962:Glucosylceramidase; C090568:imiglucerase